Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.52 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6333282 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2371368 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL6294388 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2370650 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2371272 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2371871 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2380100 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2372025 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2371133 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2371890 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200171214-A1 | BIORESORBABLE SURFACE COATING FOR DELAYING DEGRADATION | DREI LILIEN PVG GMBH & CO. KG (DE) | 2020-06-04 | — | — | US | disclosed |
| EP-3648806-A1 | BIORESORBABLE SURFACE COATING FOR DELAYING DEGRADATION | Drei Lilien PVG GmbH & Co. KG (DE) | 2020-05-13 | — | — | EP | disclosed |
| CN-102970972-B | Use of nitrocarboxylic acids for the treatment, diagnosis and prevention of aggressive healing patterns | DIETZ ULRICH (DE) | 2015-12-16 | — | — | CN | disclosed |
| CN-102970972-A | Use of nitrocarboxylic acids for the treatment, diagnosis and prevention of aggressive healing patterns | DIETZ ULRICH | 2013-03-13 | — | — | CN | disclosed |
| US-20130039956-A1 | USE OF NITROCARBOXYLIC ACIDS FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF AGGRESSIVE HEALING PATTERNS | Dietz, Ulrich (DE) | 2013-02-14 | — | — | US | disclosed |
| EP-2547322-A2 | USE OF NITROCARBOXYLIC ACIDS FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF AGGRESSIVE HEALING PATTERNS | Dietz, Ulrich (DE) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011113507-A2 | USE OF NITROCARBOXYLIC ACIDS FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF AGGRESSIVE HEALING PATTERNS | DIETZ ULRICH (DE) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039956-A1 | USE OF NITROCARBOXYLIC ACIDS FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF AGGRESSIVE HEALING PATTERNS | NOS1, NOS2, NOS3 | GPR84 1120/4885FFAR1 1269/4885MAPT 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.